<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD, Ph.D</roleName><forename type="first">Harun</forename><surname>Badakhshi</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Radiation Oncology</orgName>
								<orgName type="institution">Ernst von Bergmann Medical Center</orgName>
								<address>
									<settlement>Potsdam</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mahmoud</forename><surname>Ismail</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Surgery</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<region>German</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christos</forename><surname>Boskos</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Radiation Oncology</orgName>
								<orgName type="institution">Metaxa Anticancer Hospital Piraeus</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kuaile</forename><surname>Zhao</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Radiation Oncology</orgName>
								<orgName type="institution">Fudan University Cancer Center</orgName>
								<address>
									<settlement>Shanghai</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Kaul</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Radiation Oncology</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<address>
									<postCode>10439</postCode>
									<settlement>Kanzowstrasse 11, Berlin</settlement>
									<country key="DE">Federal Republic of Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">78D5E777A69895BD74299ECA2891D9FB</idno>
					<idno type="DOI">10.21873/anticanres.11681</idno>
					<note type="submission">Received April 8, 2017 Revised April 18, 2017 Accepted April 25, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:30+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Rectal cancer</term>
					<term>concomitant boost</term>
					<term>radiotherapy</term>
					<term>5-fluorouracil</term>
				</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract.</head><p><s>Background/Aim: This study analyzed the impact of concomitant boost on long-term clinical outcomes in locally advanced rectal cancer.</s><s>Patients and Methods: A total of 141 patients (median age=61 years) were treated with neoadjuvant chemoradiotherapy.</s><s>Median total dose was 50. <ref type="bibr" target="#b3">4</ref> Gy.</s><s>Forty-three patients received a concomitant boost.</s><s>Concurrent chemotherapy consisted of 5-fluorouracil , given as a 24-h continuous infusion.</s><s>Mean follow-up was 83.7 months.</s><s>Results: The 3, 5-, and 10-year overall survival (OS) rates were 91.9%, 84.6%, and 52.9%, respectively.</s><s>Recurrence-free survival (RFS) rates at 3, 5, and 10 years were 91.4%, 88.9%, and 79.3%, respectively.</s><s>Metastasis-free survival (MFS) rates at 3, 5, and 10 years were 84.6%, 75.4%, and 49.9%, respectively.</s><s>Overall, 9.9% of all patients achieved pathological complete response.</s><s>Down-staging of T-or N-stage was achieved in 55.1% and 41.5% of patients.</s><s>Multivariate analysis revealed that female sex (p=0.011),</s><s>concomitant boost-radiotherapy (p=0.014), and the presence of fewer than five positive lymph nodes (p&lt;0.001) were positive predictors of OS.</s><s>Fewer than five positive lymph nodes was also a positive predictor for RFS (p=0.019).</s><s>Female gender (p=0.018) and fewer than five positive lymph nodes (p&lt;0.001) were significant predictors for MFS.</s><s>Conclusion: Our data support the efficacy of preoperative treatment for rectal cancer in terms of local outcomes.</s><s>Intensified radiotherapy using a concomitant boost has a positive effect on OS.</s></p><p><s>Locally advanced rectal cancer (LARC), which involves Union Internationale Contre le Cancer (UICC) stage II and III cancer, is typically treated with neoadjuvant chemoradiotherapy, followed by total mesorectal excision (TME).</s><s>The specific radiotherapy regimen remains a topic of debate, in most European countries, as well as the United States, long-course radiotherapy (50.4 Gy) is the standard of care, whereas in most Scandinavian countries and the Netherlands, short-course radiotherapy (5×5 Gy) is administered.</s><s>Fluorouracil (5-FU) is typically used as the agent in neoadjuvant radiochemotherapy, although capecitabine is discussed as a valid alternative <ref type="bibr" target="#b0">(1)</ref>.</s></p><p><s>The benefit of adjuvant chemotherapy (CTx) in patients with LARC remains unclear.</s><s>National Cancer Centers Network guidelines recommend all LARC patients should receive adjuvant CTx, even if they have achieved a pathological complete response (pCR).</s><s>However, the The European Organisation for Research and Treatment of Cancer randomized trial 22921 did not confirm a beneficial effect for adjuvant CTx in patients with LARC after neoadjuvant chemoradiotherapy, although there was a trend towards better disease-free (DFS) and overall (OS) survival in patients with ypT0-2 disease.</s><s>Patients in whom down-staging was not achieved also did not benefit from adjuvant CTx <ref type="bibr" target="#b1">(2)</ref>.</s><s>Another retrospective analysis compared 566 patients with LARC with pCR after neoadjuvant radiotherapy or chemoradiotherapy, and detected a trend towards worse DFS in the patients administered adjuvant CTx <ref type="bibr" target="#b2">(3)</ref>.</s></p><p><s>Most national and international guidelines recommend adding a concomitant boost, based on a phase II MD Anderson trial of capecitabine plus concomitant boost radiotherapy in which better pCR, N-downstaging, and Tdownstaging rates were detected after chemoradiation with concomitant boost and oral capecitabine (4).</s><s>Other similar trials have not confirmed these findings <ref type="bibr" target="#b4">(5)</ref>, and thus, the role of concomitant boost remains a topic of debate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Methods</head><p><s>Treatment decisions, patient selection, and treatment procedures.</s><s>We performed a retrospective analysis of 141 patients who had undergone neoadjuvant chemoradiotherapy and surgery for LARC (T3/T4 with/without N+) between January 1995 and December 2009.</s><s>Followup data were analyzed until March 2011.</s><s>At our institution, treatment decisions are based on an interdisciplinary vote, and patients with LARC usually receive neoadjuvant CTx with 5-FU infusion, followed by surgery.</s><s>In the last decade, TME and postoperative 5-FU-based CTx have become standard practice at our institution.</s><s>However, since we analyzed data collected in 1995, several of this study's patients had received neoadjuvant CTx and undergone traditional surgery, which was not followed by adjuvant CTx.</s></p><p><s>Chemoradiotherapy and surgery.</s><s>At our institution, radiotherapy is performed using CT-based 3D-conformal treatment planning.</s><s>The clinical target volume (CTV) includes the tumor, the mesorectal tissue including the perirectal and presacral nodes, and the internal iliac lymph nodes <ref type="bibr" target="#b5">(6)</ref>.</s><s>All patients are irradiated in the prone position on a belly board, using a CT-planned three-field technique with 6-MV photons and a multileaf collimator.</s><s>Single fractions of 1.8 Gy/d were administered five times a week, usually up to a total dose of 45 Gy.</s></p><p><s>A sequential concomitant tumor bed boost of 5.4 Gy was introduced as standard care in our clinic, following the 2006 publication of the phase II MD Anderson trial of capecitabine plus concomitant boost radiotherapy <ref type="bibr" target="#b3">(4)</ref>.</s></p><p><s>Concomitant CTx consists of continuous 5-FU-infusion, and surgical resection, which is generally TME, is usually performed 5-6 weeks after the completion of chemoradiotherapy.</s><s>For tumors located 10 cm above the anal verge, a partial mesorectal excision (PME) is feasible, and anterior resection, intersphincteric resection, or abdominoperineal resection may also be performed, according to clinical staging and the patient's preference.</s><s>Completeness of TME is evaluated and documented by every surgeon after resection by injecting methylene blue into the superior arteria rectalis.</s></p><p><s>Adjuvant CTx usually starts 2-4 weeks after complete resection, using continuous 5-FU infusion therapy as long as there are no contraindications, such as serious impaired wound healing or anastomotic leakage.</s></p><p><s>Our current follow-up program is performed at 3, 6, 12, 18, and 24 months after surgery, and then every year for a total of 5 years.</s><s>Each visit usually includes physical examination, abdominal ultrasound, rectosigmoidoscopy, and endorectal ultrasound in cases of sphinctersaving surgery.</s><s>Pelvic CT (or magnetic resonance imaging) scans are performed at 3, 12, 24, and 36 months after surgery.</s><s>A complete colonoscopy is required at 18, 36, and 60 months after surgery.</s></p><p><s>Treatment-related toxicities are registered according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.(7).</s></p><p><s>Statistical analysis.</s><s>All statistical analyses were performed using SPSS Statistics version 19 (IBM, Armonk, NY, USA).</s><s>A p-value below 0.05 was considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Patients.</s><s>One hundred and forty-one patients with rectal cancer who had been treated in our Department between January 1995 to December 2009 were included in our analysis.</s><s>Patient characteristics are summarized in Table <ref type="table" target="#tab_0">I</ref>.</s><s>Median follow-up was 83.7 months, and the median patient age was 61 years (range=36-79 years).</s><s>Of the patients included in this study, 63% were male and 37% were female.</s><s>Clinical staging revealed 42.6% UICC stage II and 57.4% stage III cancers.</s></p><p><s>Chemoradiotherapy and surgery.</s><s>Treatment details are summarized in Table <ref type="table" target="#tab_1">II</ref>.</s><s>The median RT dose was 50.4 Gy (range=18-59.4</s><s>Gy), and all patients received single doses of 1.8 Gy.</s><s>Five patients received a total dose of 59.4 Gy instead of 50.4 Gy, and five did not receive the full planned dose due to side-effects.</s><s>In all, 139 out of 141 patients received concurrent 5-FU-based CTx by infusion; one patient refused 5-FU-based therapy.</s><s>The majority of patients (134/140) received 225 mg/m 2 5-FU.</s></p><p><s>The median interval between radiotherapy termination and surgery was 5.1 weeks (range=0.4-25.7 weeks), and the delay was longer than 8 weeks for 8.5% of patients.</s><s>Low anterior resection was performed in 73.8% of cases, abdominoperineal resection in 21.3%, and intersphincteric resection in 2.8%; 2.1% of patients were treated with other surgical methods.</s></p><p><s>Pathologic data.</s><s>The total number of examined lymph nodes was recorded for 134 (95%) patients and was unknown for seven (5%) patients.</s><s>The median number of examined nodes Significantly improved OS rates correlated with female gender (p=0.006), the application of a tumor bed boost (p=0.008),</s><s>lower ypN-stage (p&lt;0.001), and a lower number of positive lymph nodes (n=0-4 vs. n&gt;4, p&lt;0.001).</s><s>Significantly improved RFS correlated with lower ypN-stage (p=0.002).</s><s>Significantly improved MFS correlated with female gender (p=0.027),</s><s>lower ypN-stage (p&lt;0.001), and a lower number of positive lymph nodes (n=0-4 vs. n&gt;4, p&lt;0.001).</s><s>There was a trend towards improved MFS in patients who had received a tumor bed boost (p=0.06).</s><s><ref type="table" target="#tab_2">III</ref>) revealed that female gender (p=0.011),</s><s>concomitant boost-radiotherapy (p=0.014), and fewer than five positive lymph nodes (p&lt;0.001) were predictors for improved OS. Fewer than five positive lymph nodes was also a significant positive predictor for RFS (p=0.019).</s><s>Female gender (p=0.018) and fewer than five positive lymph nodes (p&lt;0.001) were both significant predictors for improved MFS.</s><s>Age, UICC stage, cT3 vs. other cT-stages, TME, pCR, and adjuvant CTx were not significantly correlated with a change in OS, RFS, or MFS rates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multivariate analysis of survival. Multivariate analysis (Table</head><p><s>Concomitant boost was the only therapy-associated factor with a significant effect on OS in both univariate and multivariate analyses.</s><s>No significant difference in UICC stage, T-stage, or N-stage was observed between patients who had received concomitant boost and patients who had received standard radiotherapy.</s><s>grade III or grade IV genitourinary toxicity was observed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acute</head><p><s>The rate of grade II or higher acute toxicity among patients who had received a boost and those who had received standard therapy was not significantly different.</s><s>Chronic toxicity.</s><s>Fifteen (10.6%) patients developed grade I gastrointestinal toxicity, and two (1.4%) developed chronic grade II gastrointestinal toxicity.</s><s>Fifteen patients (10.6%) developed chronic grade III gastrointestinal toxicity.</s><s>Nine (6.4%) patients developed chronic grade I genitourinary toxicity, and one (0.7%) developed chronic grade II genitourinary toxicity.</s><s>No chronic grade III or IV genitourinary toxicity was observed.</s><s>The rate of grade II or higher chronic toxicity among patients who had received a boost and those who had received standard therapy was not significantly different.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The incidence of rectal cancer is 15-25/100,000 per year in European countries, a number that represents approximately 35% of all colorectal malignancies.</s><s>The optimal neoadjuvant treatment for LARC is still a topic of debate.</s><s>In the past decades, OS has increased significantly.</s><s>The current standard treatment is preoperative chemoradiotherapy followed by TME and adjuvant CTx.</s><s>However, several aspects of this standard are under debate.</s><s>Questions remain regarding the meaningfulness of adding a boost in neoadjuvant radiotherapy, the optimal treatment for stage T3 rectal cancer, and whether postoperative CTx is truly beneficial.</s></p><p><s>In this study, the 3-, 5-, and 10-year OS rates were 91.9%, 84.6%, and 52.9%, respectively, and the corresponding RFS rates were 91.4%, 88.9%, and 79.3%, respectively.</s><s>Osti et al. reported a slightly lower 3-year OS (86.8%, n=65) and 3year RFS (81%) rates in patients with LARC treated with neoadjuvant chemoradiotherapy using capecitabine and concomitant boost (8), while Hernando-Requejo et al. reported a slightly higher 3-year OS (95.4%, n=74) and 3year RFS (95.4%) rates in patients with LARC treated with the same neoadjuvant chemoradiotherapy <ref type="bibr" target="#b7">(9)</ref>.</s></p><p><s>We found an acceptable toxicity profile in the current study, with non-hematological severe toxicities (grade 3 or more) observed in 10.6% of patients, and no grade 4 toxicity observed.</s><s>Other studies have shown similar rates of severe toxicity during concomitant boost radiotherapy and concurrent fluoropyrimidine-based CTx <ref type="bibr" target="#b8">(10)</ref>.</s><s>Kim et al. also reported severe (grade 3-4) non-hematological toxicities in 15.8% of patients (n=38) who had received concomitant boost radiotherapy (43.2 Gy/24 fractions plus boost 7.2 Gy/12 fractions) and associated bolus 5-FU (5).</s><s>Osti et al. also reported non-hematological severe toxicities (grade 3 or more) in 15% of their patients (n=65) <ref type="bibr" target="#b6">(8)</ref>.</s></p><p><s>In this study, 9.9% of all patients achieved pCR, although this number is slightly lower than that those of other studies.</s><s>For example, Vestermark et al. reported a pCR rate of 13% (n=52) in a phase II trial of high-dose radiotherapy (60 Gy) and Tegafur/uracil and leucovorin in patients with LARC <ref type="bibr" target="#b7">(9)</ref>.</s><s>In addition, Osti et al. reported a pCR rate of 17% (n=65) in patients with LARC treated with neoadjuvant chemoradiotherapy using capecitabine and concomitant boost (7).</s><s>Finally, Caravatta et al. described a pCR rate of 32% (n=25) in patients treated with preoperative concomitant boost radiotherapy (55 Gy/5 weeks) and concurrent CTx with raltitrexed plus oxaliplatin <ref type="bibr" target="#b9">(11)</ref>.</s><s>However, each of these studies used different CTx agents, which makes inter-study comparisons difficult.</s></p><p><s>In this study, down-staging of T-or N-stage was achieved in 55.1% and 41.5% of patients, respectively, and these results are comparable to those found in the phase II MD Anderson trial of capecitabine plus concomitant boost radiotherapy (namely 51% and 52%, respectively (4).</s><s>Osti et al. also reported similar numbers in patients with LARC treated with capecitabine and concomitant boost, with T-stage and N-stage downstaging achieved in 40% and 58% (n=65) of patients, respectively (8).</s><s>Kim et al. reported corresponding rates of 41.7% and 85.2% (n=38), respectively, in patients with LARC who had received neoadjuvant chemoradiotherapy plus concomitant boost and two cycles of bolus 5-FU and leucovorin <ref type="bibr" target="#b4">(5)</ref>.</s></p><p><s>Boost.</s><s>Most guidelines recommend that LARC be treated with adjuvant chemoradiotherapy plus boost.</s><s>These recommendations are mainly based on the phase II MD Anderson trial of capecitabine plus concomitant boost radiotherapy that reported pCR, N-, and T-downstaging of 18%, 52%, and 51%, respectively, after chemoradiation with concomitant boost (52.5 Gy/30 fractions) plus oral capecitabine (4).</s><s>Other studies have confirmed the positive effects of neoadjuvant chemoradiation with concomitant boost radiotherapy in terms of local outcomes <ref type="bibr" target="#b6">(8,</ref><ref type="bibr" target="#b8">10)</ref>.</s><s>One such study is the Madrid study of pCR in LARC after preoperative intensity modulated radiotherapy plus integrated-boost chemoradiation, which found higher rates of ypCR and pT down-staging <ref type="bibr" target="#b7">(9)</ref>.</s></p><p><s>However, other reports have described contradictory results, such as the prospective phase II KROG 04-01 trial, where the authors found that concomitant boost irradiation did not improve down-staging rates, tumor regression grades, or tumor volume reduction rates <ref type="bibr" target="#b4">(5)</ref>.</s><s>In the long-term followup, the authors reported that concomitant small-field boost irradiation for 5 weeks in patients with rectal cancer was non-superior to conventional irradiation (6 weeks) in terms of both tumor response and survival <ref type="bibr" target="#b10">(12)</ref>.</s></p><p><s>In the present study, concomitant boost was the only therapy-associated factor with a significant effect on OS in both univariate and multivariate analyses.</s><s>However, the rate of acute or chronic grade II or higher toxicity in patients who had received a boost and those who had received standard therapy was not significantly different.</s><s>Moreover, the rate of pCR was not significantly higher in patients who had received a concomitant boost.</s><s>A possible explanation might be the relatively small number of patients with pCR in the overall patient population (14 out of 141 patients) makes statistical analysis of factors influencing pCR problematic.</s><s>Furthermore, it is striking that even though concomitant boost was a significant factor for OS, the impact on RFS and MFS was not significant.</s><s>However, there was a trend towards improved MFS rates in the boost group after univariate analysis, although this trend was not confirmed by multivariate analysis.</s><s>Apart from the inherent limitations of a retrospective study, we can only speculate that the group of patients that received a boost (n=43) was too small to detect a significant change in the MFS and RFS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>Our data support the efficacy of preoperative treatment for rectal cancer in terms of local outcomes.</s><s>Intensified radiotherapy using a concomitant boost has a positive effect on OS.</s><s>Prospective studies with longer follow-up are needed to determine the efficacy of this treatment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table I .</head><label>I</label><figDesc><div><p><s>Patient characteristics (n=141).</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell></cell><cell>Value</cell></row><row><cell>Medium age (range), years Gender, n (%) UICC Stage, n (%) T-Stage, n (%) N-Stage, n (%) Localization, n (%) Histology, n (%)</cell><cell>M F II III T1 T2 T3 T4 n.a. N0 N1 N2 N+ Nx n.a. upper rectum middle rectum lower rectum Adenocarcinoma Mucinous carcinoma Undifferentiated carcinoma</cell><cell>61 (36-79) 89 (63.1) 52 (36.9) 60 (42.6) 81 (57.4) 1 (0.7) 2 (1.4) 115 (81.6) 22 (15.6) 1 (0.7) 34 (24.1) 40 (28.4) 19 (13.5) 21 (14.9) 26 (18.4) 1 (0.7) 9 (6.4) 75 (53.2) 57 (40.4) 116 (82.3) 24 (17) 1 (0.7)</cell></row><row><cell>year OS rates were 91.9%, 84.6%, and 52.9%, respectively. Corresponding RFS rates were 91.4%, 88.9%, and 79.3%, respectively, and MFS rates were 84.6%, 75.4%, and 49.9%, respectively. Only 9.9% of all patients achieved pCR. Down-staging of T-or N-stage was achieved in 55.1% and 41.5% of patients, respectively.</cell><cell></cell><cell></cell></row></table><note><p><s>UICC: Union Internationale Contre le Cancer; n.a.: not available.was12.Adequate lymph node staging according to the UICC staging system (i.e. at least 12 nodes) was reported for 64.1% of patients.Univariate analysis of survival.Univariate analysis of survival is shown in TableIII.</s><s>The 3-, 5-and 10-</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table II .</head><label>II</label><figDesc><div><p><s>Treatment characteristics.</s></p></div></figDesc><table><row><cell>Treatment</cell><cell>Dosage</cell><cell>Value</cell></row><row><cell>Neoadjuvant RT Neoadjuvant CTx, n (%) Surgery, n (%)</cell><cell>Single dose, median (range), Gy Total dose, median (range), Gy 225 mg/m 2 5-FU (infusion) 250 mg/m 2 5-FU (infusion) 825 mg/m 2 CAP LAR APR ISR Other</cell><cell>1.8 (1.8-1.8) 50.4 (18.0-59.4) 134 (95.7) 5 (3.6) 1 (0.7) 104 (73.8) 30 (21.3) 4 (2.8) 3 (2.1)</cell></row><row><cell cols="3">RT: Radiotherapy; CTx:_hemotherapy; 5-FU: 5-fluouracil; CAP: capcitabine; LAR: low anterior resection; APR: abdominoperineal resection; ISR: intersphincteric resection.</cell></row><row><cell></cell><cell></cell><cell>toxicity. Overall, treatment was well tolerated. Fifty-six (39.7%) patients developed grade I gastrointestinal toxicity, and 17 (12.1%) developed grade II. No acute grade III or grade IV gastrointestinal toxicity was observed. Thirty-five (24.8%) patients developed grade I acute genitourinary toxicity, and four patients (2.8%) developed grade II. No acute</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table III .</head><label>III</label><figDesc><div><p><s>Impact of different clinical and pathological factors on overall (OS), recurrence-free (RFS) and metastasis-free (MFS) survival.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">p-Value</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Univariate analysis</cell><cell cols="2">Multivariate analysis</cell></row><row><cell>Characterstic</cell><cell>n</cell><cell>OS</cell><cell>RFS MFS</cell><cell>OS</cell><cell>RFS MFS</cell></row><row><cell>Age &gt;60 Years ≤60 Years Gender M F UICC II III cT3 cT3 Other Boost Yes No TME Yes No pN (n) 0-4 &gt;4 ypN ypN0 ypN1 ypN2 Adjuvant CTx Yes No</cell><cell cols="5">77 64 89 0.006 ns 52 82 ns 59 115 ns 26 43 0.008 98 41 ns 100 131 &lt;0.001 ns &lt;0.001 &lt;0.001 0.019 &lt;0.001 ns ns ns ns ns ns 0.02 0.01 ns 0.018 ns ns ns ns ns ns ns ns ns ns ns ns (0.06) 0.014 ns ns ns ns ns ns ns 10 83 &lt;0.001 0.002 &lt;0.001 ns ns ns 29 18 ns ns ns ns ns ns</cell></row><row><cell cols="6">UICC: Union Internationale Contre le Cancer; M: male; F: female; TME: total mesorectal excision; CTx: chemotherapy; pN(n): number of pathological metastatic lymph nodes; ns: not significant.</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of Interests</head><p><s>The Authors declare no conflict of interest in regard to this study.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Hofheinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Post</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Matzdorff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Laechelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Link</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kettner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Hieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Lindemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Grunewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kremers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Constantin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hartung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kienle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Burkholder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="579" to="588" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Pierart M and Calais G Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group</title>
		<author>
			<persName><forename type="first">L</forename><surname>Collette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Bosset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Den Dulk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mineur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Maingon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Radosevic-Jelic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page" from="4379" to="4386" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients</title>
		<author>
			<persName><forename type="first">C</forename><surname>Capirci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cionini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Paoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Glynne-Jones</forename></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mantello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Palazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mattia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">O</forename><surname>Friso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Genovesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vidali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gambacorta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Buffoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lupattelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Favretto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>Torre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="99" to="107" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Janjan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Skibber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Rodriguez-Bigas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Wolff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Das</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Delclos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Eng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Crane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vadhan-Raj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hamilton</forename><surname>Sr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="762" to="771" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Colon Rectum</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1684" to="1691" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Preoperative shortcourse radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society</title>
		<author>
			<persName><forename type="first">R</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Wernecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kretzschmar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Loy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koswig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Schlag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">50</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Osti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Agolli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bracci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Masoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valeriani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Falco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Sanctis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Maurizi</forename><surname>Enrici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Colorectal Dis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="835" to="842" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation</title>
		<author>
			<persName><forename type="first">O</forename><surname>Hernando-Requejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lopez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cubillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ciervide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Valero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garcia-Aranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Potdevin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rubio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Strahlen Onkol</title>
		<imprint>
			<biblScope unit="volume">190</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="515" to="520" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/lleucovorin in patients with non-resectable locally advanced rectal cancer (LARC)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Vestermark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Qvortrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bisgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baatrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rasmussen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pfeiffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="428" to="433" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Caravatta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Padula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Picardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Macchia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Deodato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Massaccesi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sofo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pacelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rotondi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cecere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sallustio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Lullo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Piscopo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mignogna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cellini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Valentini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Morganti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Oncol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1151" to="1157" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Long-term followup of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Jang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="955" to="961" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
